AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
15 août 2022 08h05 HE
|
AIM ImmunoTech Inc.
– On track to commence Phase 2 study for lead program evaluating Ampligen® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022 – Well-positioned to achieve multiple near-term...
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID
28 juil. 2022 09h10 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., July 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech报告了评估安普利近（Ampligen）作为晚期胰腺癌维持疗法相关单中心指定患者研究项目的更多患者数据，与之前发布数据相比显示更多无疾病进展和整体存活情况
21 juil. 2022 14h59 HE
|
AIM ImmunoTech Inc.
安普利近®（rintatolimod）显示出作为转移性和局部晚期胰腺癌（LACC）患者系统性化疗后潜在维持疗法的具有前景的活性 新的患者数据为推进开发安普利近以用于治疗晚期胰腺癌提供了更多依据 伊拉斯姆斯医学中心C.H.J. van Eijck教授（医学博士、哲学博士）最近在荷兰伊拉默洛第五届多学科胃肠肿瘤学大会上介绍了新数据 佛罗里达州奥卡拉, July 22, 2022 (GLOBE...
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data
20 juil. 2022 08h05 HE
|
AIM ImmunoTech Inc.
Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC) ...
AIM ImmunoTech宣布最近从Jorgl活动团体收到的董事提名无效
18 juil. 2022 12h55 HE
|
AIM ImmunoTech Inc.
向联邦法院提起诉讼，以迫使活动团体透露真实意图（包括对公司的潜在敌意收购）并防止该团体继续违反联邦证券法以及美国证券交易委员会（SEC）和佛罗里达州禁令 诉状列举了某些活动团体成员的严重违法行为和违反信托责任的历史 AIM董事会因该公司存在虚假陈述和违反公司章程的遗漏而一致否决提名通知书 AIM致力于遵循所有股东的最佳利益行事，以防止活动团体在不支付溢价的情况下获得公司董事会控制权 ...
AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid
18 juil. 2022 08h00 HE
|
AIM ImmunoTech Inc.
Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of the Company – and Prevent Group from Continued Violations of Federal...
AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series
14 juil. 2022 08h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., July 14, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing
21 juin 2022 08h35 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech凭借荷兰实用新型专利的颁发巩固Ampligen®的知识产权组合。这些专利涵盖Ampligen®及其他AIM开发的用于COVID-19治疗或预防的dsRNA产品
13 juin 2022 21h36 HE
|
AIM ImmunoTech Inc.
佛罗里达州奥卡拉, June 14, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American...
AIM ImmunoTech versterkt intellectuele eigendomsportefeuille voor Ampligen® met de uitgifte van een nieuw Nederlands octrooi dat Ampligen® en andere door AIM ontwikkelde dsRNA-producten bestrijkt voor gebruik bij de behandeling of preventie van COVID-19
13 juin 2022 21h36 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., June 14, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” of het “Bedrijf”), een immunofarmaceutisch bedrijf dat zich toelegt op het onderzoek naar en de...